ASH 2017 - Acute Myeloid Leukemia

The results of the Radius-X expanded treatment protocol showed a safety profile that was consistent with that previously described in patients with FLT3 mutation–positive, newly diagnosed acute myeloid leukemia (AML).

Ivosidenib monotherapy is well-tolerated and produced durable remissions in high-risk patients with relapsed/refractory acute myeloid leukemia (AML).

Interim results of an ongoing phase 1 study showed that the addition of the selective FLT3 inhibitor quizartinib to azacitidine or low-dose cytarabine produced high overall response rates in patients with FLT3-ITD–mutated myeloid leukemias.

The preliminary results of a multicenter phase 1b dose-escalation study evaluated the safety, tolerability, and efficacy of 2 novel venetoclax-based combination therapies, in combination with the MEK inhibitor cobimetinib or the MDM2 inhibitor idasanutlin, in relapsed/refractory (R/R) acute myeloid leukemia (AML).